MRK Q2 2026 Earnings Analysis

Good disclaimer to lead with, because there's a lot to unpack here — this was a noisy quarter on paper but honestly a pretty exciting one underneath the hood.

But here's where it gets interesting — on the bottom line, Merck actually reported a loss of $0.13 per share. That sounds alarming until you realize it's almost entirely a one-time accounting quirk.

Which tanked EPS by $2.31 a share. Take that out, and the underlying business is actually performing quite well. It's a classic case of "read past the GAAP headline number."

Let's talk product performance, because this is really a story of "old reliable" versus "new and exciting." KEYTRUDA, the flagship cancer immunotherapy, grew 4% to $8.4 billion — still the workhorse, but management flagged that U.S. growth is moderating as it approaches peak penetration in a lot of indications.

Those growth rates matter a lot for the bigger narrative here, which is what happens when KEYTRUDA eventually loses patent exclusivity around the end of the decade. CEO Rob Davis addressed this directly in the Q&A — he called it "more of a hill than a cliff," with a shallow dip and a fast return to growth, backed by more than $70 billion in commercial opportunity from over 20 new products.

This is a big deal because current injectable PCSK9 drugs only reach about 5% of the eligible market — mostly because doctors and patients don't love needles for a chronic condition. An oral pill could meaningfully expand that market. Davis was clear they're not trying to steal share from injectables, they're trying to grow the whole pie — 30 million Americans are on lipid therapy but not hitting their LDL targets.

Dr. Dean Li, their research chief, made a point of saying their confidence is actually higher now than it was back in January, because so many of these pipeline bets are reading out early and positive. That's not something you hear often on earnings calls — usually it's the opposite.

But Li made a nuanced point there — he said the placebo arm barely progressed at all, which makes it statistically hard to show any drug looks better. He was pretty adamant this doesn't kill the broader thesis around targeting fibrosis with this drug in other diseases like Crohn's or hidradenitis suppurativa, where a separate study actually did hit its goals.

And a couple of near-term expectation-setters for the back half of the year. OHTUVAYRE, their COPD drug, will see a sales dip in Q3 due to inventory timing — no real demand issue, just a specialty pharmacy purchasing pattern unwinding. And Bridion, an older anesthesia drug, is actually declining slower than expected because generic competition hasn't hit as hard as anticipated — a rare bit of good news on a mature product.

So bottom line for investors — the loss per share headline looks scary, but it's a one-time deal charge, not operational weakness. The core business is growing, guidance moved up, and the pipeline story that's supposed to carry Merck through the KEYTRUDA patent cliff is de-risking faster than management even expected a few months ago.

Before we wrap — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.

Thanks for tuning in to Beta Finch — we'll catch you next time.